Developments MyoKardia’s positive Phase 2 results published in Annals of Internal Medicine MyoKardia’s (NASDAQ:MYOK) positive Phase 2 trial results of mavacamten for the treatment of obstructive hypertrophic cardiomyopathy (HCM) were recently published in the peer-reviewed journal, Annals of Internal Medicine... April 30, 2019